Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Véronique Debien

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
European Journal of Clinical Investigation|March 4, 2021
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancerElisa Agostinetto, Véronique Debien, Guilherme Nader Marta, et al.
Cancers|January 8, 2020
Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical OpportunitiesVéronique Debien, Jonathan Thouvenin, Véronique Lindner, et al.
Critical Reviews in Oncology/Hematology|December 2, 2022
Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 studyVéronique Debien, Stéphane Vignot, Christophe Massard, et al.
Cancers|July 2, 2021
HER2-Low Breast Cancer: Molecular Characteristics and PrognosisElisa Agostinetto, Mattia Rediti, Danai Fimereli, et al.
NPJ Breast Cancer|February 13, 2023
Immunotherapy in breast cancer: an overview of current strategies and perspectivesVéronique Debien, Alex De Caluwé, Xiaoxiao Wang, et al.
Therapeutic Advances in Medical Oncology|July 12, 2023
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatmentGuilherme Nader-Marta, Chiara Molinelli, Véronique Debien, et al.
Future Oncology (London, England)|August 23, 2023
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancerVéronique Debien, Virginie Adam, Elisabeth Coart, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
New-onset systemic sclerosis and scleroderma renal crisis under docetaxelVéronique Debien, Arthur Petitdemange, Dorothée Bazin, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
Journal of Clinical Medicine|February 11, 2023
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and ChallengesXiaoxiao Wang, Laetitia Collet, Mattia Rediti, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
European Journal of Clinical Investigation|March 4, 2021
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancerElisa Agostinetto, Véronique Debien, Guilherme Nader Marta, et al.
Cancers|January 8, 2020
Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical OpportunitiesVéronique Debien, Jonathan Thouvenin, Véronique Lindner, et al.
Critical Reviews in Oncology/Hematology|December 2, 2022
Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 studyVéronique Debien, Stéphane Vignot, Christophe Massard, et al.
Cancers|July 2, 2021
HER2-Low Breast Cancer: Molecular Characteristics and PrognosisElisa Agostinetto, Mattia Rediti, Danai Fimereli, et al.
NPJ Breast Cancer|February 13, 2023
Immunotherapy in breast cancer: an overview of current strategies and perspectivesVéronique Debien, Alex De Caluwé, Xiaoxiao Wang, et al.
Therapeutic Advances in Medical Oncology|July 12, 2023
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatmentGuilherme Nader-Marta, Chiara Molinelli, Véronique Debien, et al.
Future Oncology (London, England)|August 23, 2023
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancerVéronique Debien, Virginie Adam, Elisabeth Coart, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
New-onset systemic sclerosis and scleroderma renal crisis under docetaxelVéronique Debien, Arthur Petitdemange, Dorothée Bazin, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
Journal of Clinical Medicine|February 11, 2023
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and ChallengesXiaoxiao Wang, Laetitia Collet, Mattia Rediti, et al.
Pageof 2